| HCA |
Report |
2Q26 adjusted diluted EPS |
BEAT |
pred ~$7.62 vs. cons $7.47 |
HIGH |
| HCA |
Report |
2Q26 revenue |
BEAT |
pred ~$20.23B vs. cons $19.43B |
HIGH |
| HCA |
Report |
2Q26 adjusted EBITDA |
BEAT |
pred ~$4.03B vs. cons $3.95B |
MEDIUM |
| HCA |
Guide |
FY26 adjusted diluted EPS guidance |
LOWER |
guide ~$29.60 vs. cons $30.30 (FY26) |
HIGH |
| HCA |
Guide |
FY26 adjusted EBITDA guidance |
LOWER |
guide ~$15.75B vs. cons $15.95B (FY26) |
HIGH |
| HCA |
Guide |
FY26 revenue guidance |
UNCHANGED |
guide ~$78.25B vs. cons $78.20B (FY26) |
MEDIUM |
| HCA |
Guide |
FY26 health-insurance-exchange pre-tax headwind assumption |
LOWER |
guide ~($1.10B) vs. cons ~($1.00B) (FY26) |
MEDIUM |
| HCA |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| HCA |
Return |
5-day cumulative residual |
-1.5% (FADE) |
Day-1 relief is likely if final 2Q26 results remain near the preannounced ~$7.62 EPS and ~$4.03B EBITDA, but FY26 EPS guidance of roughly $29.60 versus ~$30.30 consensus leaves out-period earnings math lower; continued exchange-headwind uncertainty and weak surgery mix should drive further estimate reductions. |
MEDIUM |